Regarding the AD CSF biomarker profile, 11% of the patients had AD pathology (A+T+), 18% had an AD pathological change (A+T-), and 24% had amyloid-independent tau pathology (A-T+). This evidence concerns the gene MAPT and Alzheimer disease.